Apalutamide

{
  "id": "MLC-T-ONC-000674",
  "term": "Apalutamide",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat prostate cancer that has spread to other parts of the body and is castration sensitive (has responded to treatments that lower testosterone levels) and prostate cancer that has not spread to other parts of the body and is castration resistant (has not responded to treatments that lower testosterone levels). Apalutamide binds to proteins called androgen receptors, which are found in some prostate cancer cells. These proteins bind to androgens (male hormones) and may cause cancer cells to grow. Apalutamide blocks these proteins and may keep cancer cells from growing. It is a type of antiandrogen. Also called Erleada.",
    "A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells."
  ],
  "abbreviation": "AR antagonist ARN-509",
  "synonyms": [
    "Erleada",
    "androgen receptor antagonist ARN-509"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/apalutamide/"
}